Home›Trial›NCT07491172
NCT07491172Phase 1RECRUITING

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Study Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Conditions
CardiovascularMetabolic DiseaseDyslipidemiasLipid DisorderHypertriglyceridemiaHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed HyperlipemiaHypercholesterolaemia
Interventions / Drugs
CTX310
View on ClinicalTrials.gov ↗
Sponsor
CRSP
CRISPR Therapeutics
Gene Editing
D47/100
Study Details
Enrollment90 participants
Primary Completion—
Lead SponsorCRISPR Therapeutics AG
Data Retrieved2026-04-11 04:10:52.768013+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 90 participants
Sponsor Catalyst Profile

CRISPR Therapeutics (CRSP) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CRSP Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.